Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevuparin for acute vaso-occlusive crisis in sickle-cell disease
NL-OMON46980Phase 2Active, not recruiting
- Sponsor
- Modus Therapeutics
- Start
- Oct 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) comparing Sevuparin infusion with Placebo infusion (2 arms). Primary endpoint: Time to vaso-occlusive crisis resolution. Started Oct 2015; status: active, not recruiting.
02
Drugs
sevuparin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON46980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46980.